MiMedx Net Cash Flow 2010-2025 | MDXG

MiMedx net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

MiMedx Net Cash Flow 2010-2025 | MDXG

MiMedx net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$226.7B
Amgen (AMGN)$158.7B
Gilead Sciences (GILD)$139.7B
Vertex Pharmaceuticals (VRTX)$117.3B
Bristol Myers Squibb (BMY)$88.1B
CSL (CSLLY)$84.3B
GSK (GSK)$75.8B
Regeneron Pharmaceuticals (REGN)$58.9B
Alnylam Pharmaceuticals (ALNY)$51.1B
Argenex SE (ARGX)$41B
BioNTech SE (BNTX)$25.8B
Royalty Pharma (RPRX)$20.7B
Insmed (INSM)$20.4B
Biogen (BIIB)$18.8B
Illumina (ILMN)$16.3B
Genmab (GNMSF)$14.7B
Incyte (INCY)$14.6B
Genmab (GMAB)$13.9B
Moderna (MRNA)$11.4B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$11B
Ascendis Pharma (ASND)$10.6B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Halozyme Therapeutics (HALO)$7.4B